- Home
- NBXG vs CAPR Comparison
NBXG vs CAPR Comparison
Compare NBXG & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBXG
- CAPR
- Stock Information
- Founded
- NBXG 2021
- CAPR 2005
- Country
- NBXG United States
- CAPR United States
- Employees
- NBXG N/A
- CAPR N/A
- Industry
- NBXG Trusts Except Educational Religious and Charitable
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NBXG Finance
- CAPR Health Care
- Exchange
- NBXG Nasdaq
- CAPR Nasdaq
- Market Cap
- NBXG 1.0B
- CAPR 867.6M
- IPO Year
- NBXG N/A
- CAPR N/A
- Fundamental
- Price
- NBXG $12.74
- CAPR $13.07
- Analyst Decision
- NBXG
- CAPR Strong Buy
- Analyst Count
- NBXG 0
- CAPR 7
- Target Price
- NBXG N/A
- CAPR $39.29
- AVG Volume (30 Days)
- NBXG 243.7K
- CAPR 1.8M
- Earning Date
- NBXG 01-01-0001
- CAPR 11-13-2024
- Dividend Yield
- NBXG 10.25%
- CAPR N/A
- EPS Growth
- NBXG N/A
- CAPR N/A
- EPS
- NBXG N/A
- CAPR N/A
- Revenue
- NBXG N/A
- CAPR $23,228,045.00
- Revenue This Year
- NBXG N/A
- CAPR N/A
- Revenue Next Year
- NBXG N/A
- CAPR $74.85
- P/E Ratio
- NBXG N/A
- CAPR N/A
- Revenue Growth
- NBXG N/A
- CAPR 65.33
- 52 Week Low
- NBXG $9.31
- CAPR $3.52
- 52 Week High
- NBXG $12.23
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- NBXG 36.47
- CAPR 37.42
- Support Level
- NBXG $13.09
- CAPR $12.25
- Resistance Level
- NBXG $13.25
- CAPR $20.75
- Average True Range (ATR)
- NBXG 0.22
- CAPR 1.62
- MACD
- NBXG -0.08
- CAPR -0.24
- Stochastic Oscillator
- NBXG 14.01
- CAPR 9.65
About NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.